Want to see JP:3151 full AI Analyst Report?
Top Page
Vital KSK Holdings, Inc.
(3151)
Select Model
Select Model
Rating:67Neutral
Price Target:
¥1,751.00
▲(27.81% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by solid fundamentals (low and improving leverage and improving profitability) offset by inconsistent cash-flow generation and thin margins. Valuation is a meaningful positive due to the moderate P/E and strong dividend yield, while technical indicators are neutral-to-slightly-positive with limited near-term momentum.
Positive Factors
Low and improving leverage
A declining debt burden and low leverage strengthen financial resilience, reduce interest and refinancing risk, and give the distribution business greater flexibility to fund operations through varying market and working-capital conditions.
Negative Factors
Volatile cash generation
Large swings in operating and free cash flow indicate inconsistent conversion of accounting earnings into cash, likely linked to working capital or timing. This can constrain reinvestment, dividends, and balance-sheet flexibility despite reported profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low and improving leverage
A declining debt burden and low leverage strengthen financial resilience, reduce interest and refinancing risk, and give the distribution business greater flexibility to fund operations through varying market and working-capital conditions.
Read all positive factors
Vital KSK Holdings, Inc. (3151) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥75.19B
Dividend Yield4.17%
Average Volume (3M)121.33K
Price to Earnings (P/E)11.6
Beta (1Y)0.34
Revenue Growth2.43%
EPS Growth1.19%
CountryJP
Employees3,871
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)145.39
Shares Outstanding51,902,977
10 Day Avg. Volume69,970
30 Day Avg. Volume121,326
Financial Highlights & Ratios
PEG Ratio4.38
Price to Book (P/B)0.60
Price to Sales (P/S)0.12
P/FCF Ratio63.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vital KSK Holdings, Inc. Business Overview & Revenue Model
Company Description
Vital KSK Holdings, Inc. is a Japanese entity primarily involved in the wholesale distribution of pharmaceutical products. Its diverse wholesale operations also cover veterinary medications, agricultural chemicals and supplies, and various types o...
Vital KSK Holdings, Inc. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
82
Very Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 616.92B | 610.50B | 600.37B | 587.48B | 579.77B | 577.25B |
| Gross Profit | 50.24B | 49.58B | 49.22B | 48.30B | 44.96B | 43.98B |
| EBITDA | 13.46B | 8.08B | 14.56B | 12.16B | 11.56B | 10.87B |
| Net Income | 7.03B | 7.36B | 7.31B | 5.84B | 4.83B | 4.77B |
Balance Sheet | ||||||
| Total Assets | 322.29B | 320.57B | 299.43B | 317.26B | 297.32B | 313.03B |
| Cash, Cash Equivalents and Short-Term Investments | 22.76B | 22.95B | 23.10B | 34.71B | 19.03B | 26.97B |
| Total Debt | 5.57B | 6.78B | 7.70B | 10.15B | 10.87B | 12.59B |
| Total Liabilities | 206.37B | 201.86B | 192.12B | 211.31B | 197.15B | 212.99B |
| Stockholders Equity | 114.41B | 117.22B | 105.91B | 104.66B | 98.99B | 98.96B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.11B | -10.59B | 18.47B | -9.60B | 3.35B |
| Operating Cash Flow | 0.00 | 4.83B | -8.02B | 23.57B | -3.00B | 7.49B |
| Investing Cash Flow | 0.00 | -1.07B | 3.52B | -1.82B | -1.04B | -2.01B |
| Financing Cash Flow | 0.00 | -4.40B | -6.54B | -5.77B | -4.08B | -8.49B |
Vital KSK Holdings, Inc. Technical Analysis
Positive
1370.00
Price Trends
1595.42
Positive
1546.33
Positive
1445.87
Positive
Market Momentum
16.07
Negative
63.31
Neutral
86.73
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3151, the sentiment is Positive. The current price of 1370 is below the 20-day moving average (MA) of 1631.70, below the 50-day MA of 1595.42, and below the 200-day MA of 1445.87, indicating a bullish trend. The MACD of 16.07 indicates Negative momentum. The RSI at 63.31 is Neutral, neither overbought nor oversold. The STOCH value of 86.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3151.
Vital KSK Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥45.49B | 11.40 | ― | 2.63% | 5.16% | 37.79% | |
67 Neutral | ¥75.19B | 11.56 | ― | 4.22% | 2.43% | 1.19% | |
66 Neutral | ¥9.57B | 14.46 | ― | 1.87% | -0.52% | 3.87% | |
64 Neutral | ¥41.88B | 12.83 | ― | 0.91% | 6.17% | -33.01% | |
62 Neutral | ¥11.41B | 9.97 | ― | 3.90% | 3.17% | -22.27% | |
52 Neutral | ¥14.51B | 18.67 | ― | 1.83% | 2.87% | -73.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:3151
Vital KSK Holdings, Inc.
1,680.00
492.10
41.43%
JP:2689
OLBA HEALTHCARE HOLDINGS, Inc.
1,871.00
-71.48
-3.68%
JP:3417
Ohki Health Care Holdings, Inc.
1,025.00
-219.54
-17.64%
JP:6062
Charm Care Corporation
1,412.00
374.69
36.12%
JP:7071
Amvis Holdings.Inc.
413.00
-201.93
-32.84%
JP:9265
YAMASHITA HEALTH CARE HOLDINGS, INC.
3,750.00
734.55
24.36%
Vital KSK Holdings, Inc. Corporate Events
Vital KSK Holdings Posts Higher Sales but Sharp Profit Drop in First Quarter
Aug 6, 2026
Vital KSK Holdings reported first-quarter consolidated net sales of ¥154.6 billion, up 4.3% year on year, but saw declines in profitability, with core operating profit down 6.4% and profit attributable to owners of parent falling 48.2% to ...
Vital KSK Holdings Continues Share Buyback Under Multi-Billion Yen Authorization
Aug 3, 2026
Vital KSK Holdings, Inc. has reported the execution of a share repurchase program, buying back 241,500 common shares for a total of ¥386.7 million between July 1 and July 31, 2026 through market purchases under discretionary investment manage...
Vital KSK Holdings to Book ¥8.1 Billion Extraordinary Gain on Share Sales
Jul 27, 2026
Vital KSK Holdings, Inc., a TSE Prime Market-listed company based in Tokyo, operates through consolidated subsidiaries that hold listed investment securities as part of its broader asset management activities. The group is currently reviewing cros...
Vital KSK Completes Treasury Share Disposal for Performance-Linked Stock Plan
Jul 24, 2026
Vital KSK Holdings has completed the payment procedures for the disposal of its treasury shares used as performance-linked restricted stock compensation, following a resolution by its board of directors in late June 2026. This move reflects the co...
Vital KSK Holdings Details Progress of Share Buyback Program
Jul 1, 2026
Vital KSK Holdings, Inc. has disclosed the status of its ongoing share repurchase program, conducted under provisions of Japan’s Companies Act and authorized by its board. The company is buying back common shares through market purchases, re...
Vital KSK to Dispose of Treasury Shares for Performance-Linked Restricted Stock Plan
Jun 25, 2026
Vital KSK Holdings, Inc. has approved the disposal of 34,618 shares of its treasury stock as part of a performance-linked restricted stock compensation plan for a wide range of group personnel. The shares, valued at a total of ¥53.69 million ...
Vital KSK Begins Share Buyback Under ¥4 Billion Authorization
Jun 1, 2026
Vital KSK Holdings has disclosed the status of its ongoing share repurchase program, executing buybacks of 118,300 common shares for a total of ¥182.76 million between May 15 and May 31, 2026, via market purchases under discretionary investme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.